格隆汇11月20日丨百奥赛图-B(02315.HK)发布公告，中国证监会已于2025年10月15日批准公司的A股发 行注册的申请。根据中国适用法律及法规的规定，公司及主包销商将于初步询价日(即2025年11月25日 (九时三十分至十五时正))在中国向符合中国法律及法规规定的询价对象进行初步询价，以厘定发行价 格。建议A股发行的最终规模及发行价格一经厘定，公司将另行刊发公告。 ...

智通财经APP讯，百奥赛图-B(02315)发布公告，诚如本公司日期为2025年10月16日的公告所披露，中国 证监会已于2025年10月15日批准本公司的A股发行注册的申请。根据中国适用法律及法规的规定，本公 司及主包销商将于初步询价日(即2025年11月25日(九时三十分至十五时正))在中国向符合中国法律及法 规规定的询价对象进行初步询价，以厘定发行价格。建议A股发行的最终规模及发行价格一经厘定，本 公司将另行刊发公告。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 本公司已於2025年11月20日就建議A股發行提交了《首次公開發行股票並在科創 板上市招股章程》（「A股招股意向書」）以及相關材料。A股招股意向書及相關材料 已刊載於上交所科創板股票發行上市審核網站( kcb.sse.com.cn )。 1 A股招股意向書載有（其中包括）本公司及其附屬公司於截至2025年9月30日止九 個月之綜合財務資料（「綜合財務資料」）。綜合財務資料乃依據中華人民共和國財 政部頒布的《企業會計準則》編製，並經畢馬威華振會計師事務所（特殊普通合夥） 審閱，詳情如下： | 於2025年 | | 於2024年 | | | | --- | --- | --- | --- | --- | | 9 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 內幕消息 建議A股發行的初步詢價期 及 A股招股意向書主要條文概要 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）遵照香港聯合交易所 有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例（香港法 例第571章）第XIVA部的內幕消息條文（定義見上市規則）而發出。 誠如本公司日期為2025年10月16日的公告所披露，中國證監會已於2025年 10月15日批准本公司的A股發行註冊之申請。根據中國適用法律及法規的規 定，本公司及主包銷商將於初步詢價日（即2025年11月25日（九時三十分至十 五時正））在中國向符合中國法律及法規規定的詢價對象進行初步詢價，以釐 定發行價格。建 ...

百奥赛图（北京）医药科技股份有限公司（以下简称"百奥赛图""发行人"或"公司"）首次公开发行股票 并在科创板上市的申请已经上海证券交易所（以下简称"上交所"）科创板上市委员会审议通过，并已经 中国证券监督管理委员会（以下简称"中国证监会"）证监许可〔2025〕2296号文同意注册。《百奥赛图 （北京）医药科技股份有限公司首次公开发行股票并在科创板上市招股意向书》及附录在上海证券交易 所网站（www.sse.com.cn）和符合中国证监会规定条件网站（中国证券网，网址www.cnstock.com；中 证网，网址www.cs.com.cn；证券时报网，网址www.stcn.com；证券日报网，网址www.zqrb.cn；经济参 考网，网址www.jjckb.cn；中国金融新闻网，网址www.financialnews.com.cn；中国日报网，网址 cn.chinadaily.com.cn）披露，并置备于发行人、本次发行保荐人（主承销商）中国国际金融股份有限公 司的住所，供公众查阅。 敬请投资者重点关注本次发行流程、网上网下申购及缴款、弃购股份处理等方面，并认真阅读同日披露 于上交所网站和符合中国证监会规定条件 ...

Group 1 - The core point of the article is that Bai'ao Saitou (688796.SH) has released its prospectus for an initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 47.5 million shares, which will account for 10.63% of the total share capital post-issue [1] - The company was established in 2009 and operates as a preclinical CRO and biotechnology firm, providing innovative animal models and preclinical drug development services based on its proprietary gene editing technology [1][2] - The company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models, expanding its business into innovative animal sales, preclinical pharmacology evaluation services, and antibody drug collaboration [2] Group 2 - The company's main business revenue for the reporting periods were 533 million yuan, 716 million yuan, 980 million yuan, and 621 million yuan, with a compound annual growth rate of 35.56% from 2022 to 2024 [2] - The funds raised from the IPO, after deducting issuance costs, will be invested in projects including early drug development service platform construction, antibody drug research and evaluation, preclinical research projects, and supplementing working capital, totaling 1.185 billion yuan [3]

Core Viewpoint - The company, BaiOsaite (688796.SH), has announced its initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 47.5 million shares, which represents 10.63% of the total share capital post-issue [1] Group 1: Company Overview - Established in 2009, the company operates as a preclinical Contract Research Organization (CRO) and biotechnology firm, focusing on gene editing technology to provide innovative model animals and preclinical drug development services [1] - The company has developed the RenMice platform, which includes various series of fully human antibodies/TCR mice, aimed at large-scale drug discovery targeting over a thousand potential drug targets [1] - The company has evolved into a comprehensive entity with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Performance - As of the reporting period, the company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models [2] - The company’s innovative model animals and cell products include humanized mouse models targeting immune checkpoints and cytokines, severe immunodeficient mice, various spontaneous disease models, and human-derived cell lines, covering areas such as tumors, autoimmune diseases, metabolism, and neurology [2] - The company's main business revenues for the reporting periods were 533 million yuan, 716 million yuan, 980 million yuan, and 621 million yuan, with a compound annual growth rate of 35.56% from 2022 to 2024 [2] Group 3: Fundraising and Investment Plans - The funds raised from the IPO, after deducting issuance costs, will be allocated to several projects in order of priority: early drug development service platform construction, antibody drug research and evaluation, preclinical research projects, and supplementing working capital, with a total investment amount of 1.185 billion yuan [3]

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 於2025年11月19日舉行之 2025年第一次臨時股東大會投票表決結果 茲提述百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）的通函（「該通函」）， 當中載有（其中包括）日期為2025年11月3日的2025年第一次臨時股東大會（「臨時 股東大會」）通告（「通告」）。除文義另有所指外，本公告所用詞彙與該通函所界定 者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會謹此宣佈，本公司已於2025年11月19日（星期三）上午十時正假座中國北 京市大興區大興生物醫藥產業基地寶參南街12號院會議室以現場會議結合網上虛 擬會議的方式舉行臨時股東大會。臨時股東大會乃根據中國公司法及公司章程的 規定舉行。 於臨時股東大會日期，本公司的已發行股份總 ...

Core Viewpoint - The company leverages gene editing technology to create a comprehensive antibody drug development platform, focusing on innovative solutions and high-quality antibody molecules targeting over 1,000 epitopes [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 621 million yuan, representing a year-on-year growth of 51.3%, with a gross margin maintained at a high level of 74.4% [1]. - The company is expected to turn a profit for the first time in 2024, with a net profit of approximately 48 million yuan in the first half of 2025 [1]. - Revenue from preclinical animal products and pharmacodynamic services is a solid foundation, with sales of model animals reaching 274 million yuan in the first half of 2025, a year-on-year increase of 56% [1]. Group 2: Business Development - The company has established partnerships with all of the top ten global pharmaceutical companies, leveraging its expertise in gene editing and model animals [2]. - The antibody development business has become the core driver of revenue growth, with a compound annual growth rate (CAGR) of 53% from 2021 to 2024, and revenue of 163 million yuan in the first half of 2025, up 38% year-on-year [2]. - The company has signed approximately 280 agreements for cooperation, authorization, or transfer of antibody molecules as of the first half of 2025, with 61 projects already transferred or authorized [2]. Group 3: Future Outlook - Revenue growth is projected at 45%, 36%, and 35% for 2025 to 2027, with net profit growth expected at 323%, 103%, and 75% respectively [3]. - The company is anticipated to generate revenues of 1.42 billion yuan, 1.93 billion yuan, and 2.61 billion yuan in 2025, 2026, and 2027, respectively, with a current market value corresponding to price-to-sales ratios of 7.6, 5.6, and 4.1 [3]. - Given the high growth potential and solid foundation of the preclinical animal and pharmacodynamic evaluation business, the company is rated as a "buy" [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2025年11月6日 本月底法定/註冊股本總額： RMB 399,398,420 FF301 第 1 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 110,781,920 | | | 0 | | 110,781,920 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | 110,781, ...